REFERENCES
- Arslan M., Evrensel T., Kurt E., Demiray M., Ercan I., Kanat O., Ozkan A., Manavoglu O. Comparison of the serum erythropoietin levels in chemotherapy-naive and cisplatin-treated cancer patients. Neoplasma 2005; 52: 43–45
- Anat H., Inanc S. E., Dalay N., Karaloglu D., Erturk N., Yasasever V. Effect of cisplatin on erythropoietin and iron changes. Eur. J. Cancer. 1993; 29: 777
- Baliga R., Zhang Z., Baliga M., Ueda N., Shah S. V. In vitro and in vivo evidence suggesting a role for iron in cisplatin-induccd nephrotoxicity. Kidney Int. 1998; 53: 394–401
- Bokkel Huinink W. W., Swart C. A., Van Toorn D. W., Morack G., Breed W. P., Hillen H. F., van der Hoeven J. J., Reed N. S, Fairlamb D. J., Chan S. Y., Godfrey K. A., Kristensen G. B., van Tinteren H., Ehmer B. Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med. Oncol. 1998; 15: 174–182
- Canaparo R., Casale F., Muntoni E., Zara G. P., Pepa C. D., Berno E., Pons N., Fomari G., Eandi M. Plasma erythropoietin concentrations in patients receiving intensive platinum or nonplatinum chemotherapy. Br. J. Clin. Pharmacol. 2000; 50: 146–153
- Cazzola M. Mechanisms of anaemia in patients with malignancy: implications for the clinical use of recombinant human erythropoietin. Med. Oncol 2000; 17(Suppl 1)s11–16
- Cerruti A., Castello G., Balleari E., Bogliolo G., Lerza R. Pannacciulli, I. Serum erythropoietin increase in patients receiving adjuvant therapy with 5-fluorouracil and leucovorin. Exp. Hematol. 1994; 22: 1261–1263
- Hasegawa I., Tanaka K. Serum erythropoietin levels in gynecologic cancer patients during cisplatin combination chemotherapy. Gynecol. Oncol. 1992; 46: 65–68
- Heddens D., Alberts D. S., Hannigan E. V., Williams S. D., Garcia D., Roe D. J., Bell J., Alvarez R. D. Prediction of the need for red cell transfusion in newly diagnosed ovarian cancer patients undergoing platinum-based treatment. Gynecol. Oncol. 2002; 86: 239–243
- Maxwell P. H., Osmond M. K., Pugh C. W., Heryet A., Nicholls L. G., Tan C. C., Doe B. G., Ferguson D. J., Johnson M. H., Ratcliffe P. J. Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney Int. 1993; 44: 1149–1162
- Mujais S. K., Beru N., Pullman T. N., Goldwasser E. Erythropoietin is produced by tubular cells of the rat kidney. Cell Biochem. Biophys. 1999; 30: 153–166
- Pedain C., Herrero J., Kunzel W. Serum erythropoietin level in ovarian cancer patients receiving chemotherapy. Eur. J. Obstet. Gynecol. Reprod. Biol. 2001; 98: 224–230
- Schuster S. J., Koury S. T., Bohrer M., Salceda S., Caro J. Cellular sites of extrarenal and renal erythropoietin production in anaemic rats. Br. J. Haem. 1992; 81: 153–159
- Wood P. A., Hrushesky W. J. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J. Clin. Invest. 1995; 95: 1650–1659
- Yildirim Z., Sogut S., Odaci E., Iraz M., Ozyurt H., Kotuk M., Akyol O. Oral erdosteine administration attenuates cisplatin-induced renal tubular damage in rats. Pharmacol. Res. 2003; 47: 149–156
- Zhang J. G., Viale M., Esposito M., Lindup W. E. Tiopronin protects against the nephrotoxicity of cisplatin in the rat. Hum. Exp. Toxicol. 1999; 18: 713–717